Jing He

Jing He from Truist Securities asked about the specific details to be presented at the SGO conference in April regarding the ROSELLA trial data, including the full Kaplan-Meier curve, subgroup analyses, and comprehensive safety tables. She also inquired how these detailed results are expected to drive early adoption of relacorilant in oncology.

Answer

William Guyer, Chief Development Officer, confirmed that the SGO presentation would include the full Kaplan-Meier curve and comprehensive safety data, noting that the safety profile remains consistent and well-tolerated compared to previous analyses. Roberto Vieira, President of Oncology, highlighted the transformative 35% reduction in risk of death and 4.1-month median overall survival extension as unprecedented for this refractory patient population. He emphasized relacorilant's favorable safety profile (single-digit discontinuation) and oral administration, projecting very early and broad adoption to establish a new standard of care.

Jing He, on behalf of Joon Lee, asked about the expected details of the ROSELLA data presentation at the upcoming SGO meeting in April, including specific subgroup or safety analyses, full safety tables, and how these findings are anticipated to support early adoption of relacorilant in oncology.

Answer

Bill Guyer, Chief Development Officer, stated that the SGO presentation would include the full Kaplan-Meier curve showing patient survival and arm separation, along with comprehensive safety data sets, which are expected to be very similar to previous analyses, demonstrating relacorilant's tolerability. Roberto Vieira, President of Oncology, highlighted the transformative 35% reduction in risk of death and 4.1-month extension in median overall survival, noting that relacorilant added minimal safety burden and is an oral therapy. He expressed expectations for very early and broad adoption, potentially establishing a new standard of care.